A Phase I/II Study of Durvalumab and Chemoradiation before Surgery for Esophageal Cancer

Full Title

Phase Ib/II study of induction chemotherapy and durvalumab (MEDI4736) and tremelimumab with chemoradiation for esophageal and gastroesophageal junction adenocarcinoma

Purpose

The purpose of this study is to assess the safety of adding the drug durvalumab (also called MEDI4736) to chemoradiation using two standard chemotherapy drugs, carboplatin and paclitaxel, before surgery in patients with cancers of the esophagus or the junction between the esophagus and stomach (gastroesophageal junction). The medications used in this study are given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must:

• Have operable esophageal or gastroesophageal cancer.
• Have not had prior chemotherapy.
• Have an ECOG status of 0 or 1.
• Be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Geoffrey Ku at 646-888-4588.